- Home
- TOMZ vs BLRX Comparison
TOMZ vs BLRX Comparison
Compare TOMZ & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOMZ | BLRX |
|---|---|---|
| Founded | 1979 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 12.0M |
| IPO Year | 2009 | 2010 |
Fundamental Metrics
Financial Performance| Metric | TOMZ | BLRX |
|---|---|---|
| Price | $1.68 | $2.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 17.8K | 15.2K |
| Earning Date | 05-12-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,635,927.00 | N/A |
| Revenue This Year | $48.56 | N/A |
| Revenue Next Year | $121.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $2.15 |
| 52 Week High | $2.12 | $4.56 |
Technical Indicators
Market Signals| Indicator | TOMZ | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.67 | 44.20 |
| Support Level | $1.64 | $2.64 |
| Resistance Level | $1.95 | $3.08 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 17.96 | 16.36 |
Price Performance
Historical ComparisonAbout TOMZ TOMI Environmental Solutions Inc.
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.